RxDoctor Payments Data

Raouf Hilal, MD

Gastroenterology · Maitland, FLNPI 1427161793

Payments from drug & device makers

$13,099in general payments, 2019–2025

Across 719 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Bristol Myers Squibb$849
  • Pfizer$827
  • Phathom Pharmaceuticals, Inc.$757
  • Gilead$544
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$240%
  • Food & beverage$13,058100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,099 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$109,425
Medicare patients
385
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$1,112,555
CreonLipase/Protease/Amylase78$360,291
EpclusaSofosbuvir/Velpatasvir11$267,441
LinzessLinaclotide240$180,627
ZenpepLipase/Protease/Amylase25$173,909
EntyvioVedolizumab16$135,114
XifaxanRifaximin37$112,393
Humira(Cf) PenAdalimumab13$85,757
VoqueznaVonoprazan Fumarate39$24,631
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates271$17,293
Mesalamine30$13,596
Rifabutin28$7,747
TrulancePlecanatide13$7,633
ClenpiqSod Picosulf/Mag Ox/Citric Ac42$7,240
Pantoprazole Sodium535$6,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex, Entyvio$436$1,247,67028 claims
AbbVieCreon, Linzess$4,302$540,918318 claims
GileadEpclusa$544$267,44111 claims
Aimmune Therapeutics, Inc.Zenpep$396$173,90925 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,459$120,02650 claims
Phathom Pharmaceuticals, Inc.Voquezna$757$24,63139 claims
Ferring Pharmaceuticals Inc.Clenpiq$106$7,24042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →